We have examined
The antibodies to the AChR in myasthenic sera are heterogeneous, and the poor correlation between their titer and the severity of the disease (Lindstrom et al., 1976; Vincent and Newsom-Davis, 1980; Roses et al., 1981) suggests that only certain classes of them are deleterious. One class in which the concentration correlates with the clinical state of the disease is that of the antibodies that inhibit the binding of a-bungarotoxin (mu-BuTx) to the AChR (Drachman et al., 1982) .
In addition to their importance in the pathophysiology of the disease, myasthenic antibodies can also serve as useful tools for investigating the structure and regulation of the AChR. Sera from most patients, for example, have antibodies that distinguish the AChRs in the extrajunctional membranes of developing or denervated mammalian muscle from those at mature endplates (Almon et al., 1974; Bender et al., 1975; Weinberg and Hall, 1979; Dwyer et al., 1981; Lefvert, 1982) . Although the AChR is extremely well characterized biochemically, the specificities of myasthenic antibodies have been defined at a molecular level only in a few instances (Tzartos et al., 1982) and their use as structural probes of the AChR has been limited.
We have recently described a myasthenic serum with an unusually high degree of specificity for AChRs in the extrajunctional membranes of developing and denervated muscle. The antibodies in this serum also bind AChRs at developing endplates in rat muscle until the third postnatal week (Hall et al., 1985) . The specificity of these antibodies is even more striking in that they appear to bind almost exclusively at or near the toxin-binding sites on the receptor (Hall et al., 1985) . The AChR has two toxin-binding sites, which are associated with each of the two a-subunits of the AChR (Karlin, 1980; Haggerty and Froehner, 1981; Conti-Tronconi and Raftery, 1982; Oblas et al., 1983; Gershoni et al., 1983.) In muscle cells, these two sites can be distinguished by agonists and antagonists of the AChR, although not by the toxin itself (Sine and Taylor, 1979 , 1980 , 1981 . We report here experiments in which we have used a mouse muscle cell line, C2, to investigate the specificity of the myasthenic serum for the two toxin-binding sites of the AChR in situ. In the following paper (Maricq et al., 1985) we examine the effects of the serum on the functional response of C2 AChRs to agonists. Some of the experiments described here have been reported in a preliminary communication (Hall et al., 1983) .
Materials and Methods
Myasthenic antibodies. The antibodies have been described previously (Hall et al., 1983 (Hall et al., , 1985 Other reagents. Monoiodinated ?ol-BuTx was prepared and purified as previously described (Inestrosa et al., 1983) . Rhodamine-conjugated or-BuTx was prepared as described by Ravdin and Axelrod (1977) . d-Tubocurarine (dTC) was from Calbiochem.
An antiserum to the myasthenic antibodies was raised in rabbits using a DEAE fraction of the myasthenic antibody preparation prepared as described by Hall et at. (1985) .
Tissue culture. The C2 mouse cell line, originally isolated by Yaffe and Saxel (1977) was maintained as described by lnestrosa et al. (1983) . Myoblasts were grown in a medium consisting of Delbecco's modified Eagle's medium with 1 gm/liter of glucose (DME H-16) (GIBCO), supplemented with 20% fetal calf serum (GIBCO) and 0.5% chick embryo extract (GIBCO; growth medium). To stimulate cell differentiation, growth medium was replaced by DME H-16 supplemented with 10% horse serum (GIBCO; fusion medium).
Within several days, large multinucleated myotubes appeared with AChRs on their surfaces (Inestrosa et al., 1983) .
of CX-BuTx binding was monitored with or without pretreatment of the cells with the antibody.
After incubation with 4 mg/ml of antibody or buffer for 2 hr at 37°C cells were rinsed as above and preincubated with various concentrations of dTC or buffer for 20 min at room temperature. The medium was then replaced by the same medium containing 10 nM '251-a-BuT~. Afler 10 min the binding reaction was stopped, the cells were washed, and the amount of bound toxin was determrned as described above. Control experiments established that the formation of toxin-receptor complex was linear with time during this period (see Fig. 6 ). The inhibition data were fit to a twosite model for antagonist binding as described by Sine and Taylor (1981) :
Except where noted, myoblasts were plated in 24-well plastic tissue culture plates (Falcon) at a density of about 3000 cells/cm'.
For measurement of AChR turnover, the wells were precoated with collagen to increase the attachment of cells to the dish. For immunohistochemical staining, the myoblasts were plated on plastic coverslips in 24-well plates. In all cases the growth medium was replaced by fusion medium after 48 hr, and the cultures were used for experiments within the next 4 days. Kinetics of a-toxin binding in normal and antibody-treated cells. The general procedures for studying cu-BuTx binding to C2 cells was similar to that described by Sine and Taylor (1979) for BC3H-1, a non-fusing mouse muscle cell line. Fusion medium was removed from C2 myotubes, and the cells were equilibrated for 20 min at room temperature in Buffer A consisting of 140 mM NaCI, 5.4 mM KCI, 1.8 mM CaCI,, 1.7 mM MgS04, 1.0 mM N&HP04, 5.5 mM glucose, 25 mM HEPES, and 66 pg/ml of bovine serum albumin, pH 7.4. The binding reaction was initiated by transferring the cells to the same medium containing 10 nM '251-c+B~T~. The reaction was terminated at various intervals by aspiration, followed by three l-ml washes with Buffer A. Cells were then extracted twice in 0.5 ml of 0.1 N NaOH, and the combined extracts were counted in a Beckman II gamma counter. The total number of cu-BuTx-binding sites was determined by incubating the cells with '*51-~-B~T~ for 3 hr under the same conditions.
The association rate constant, k,, was calculated using the integrated form of the second-order rate equation, where kobB and k, are the association rate constants for a-BuTx binding to the AChR in the presence and absence, respectively, of dTC at concentration L, and Nn and Na are the relative fractions of binding sites for dTC with dissociation constants of Kn and Ke, respectively.
In the absence of antibody, Na and A!a were both assumed to be equal to 0.5, and the values for Kn and Ke were obtained by linear regression, treating the two extreme portions of the curve separately.
Because the difference between KA and Ke was so large, the equation could be simplified to linear equations at the two extremes of the curve. In experiments involving antibody treatment, data were analyzed by assuming that Kn and KS were unchanged.
The values for Nn and Ns were calculated from the data for total toxin binding inhibition according to different models for the binding of antrbody (see "Results").
ACM? degradation. C2 myotubes grown in collagen-coated 24-well plates were rinsed and incubated with buffer or antibody (4 to 6 mg/ml). The receptor was then labeled with '?a-BuTx by incubation with 10 nM toxin for 2 hr. After extensrve washing to remove free toxin, the myotubes were incubated in 0.5 ml of fusion medium at 37'C. At intervals of 1 to 3 hr the culture medium was replaced by 0.5 ml of fresh medium, counted, and frozen for later analysis. At the end of the experiment, the cells were extracted twrce with 0.5 ml of 0.1 N NaOH and the combined extracts were counted. The radioactivity released into the medium at each time point was analyzed by P-2 column chromatography to separate degradation products from intact toxin that had been released by dissociation of toxin-receptor complex. The data for degradation and dissociation were then plotted separately on a semilog plot as percentage of total toxin bound. Because both degradation and dissociation affect the same population of toxin-receptor complex, this method of graphical analysis is not rigorously correct; however, it does allow a comparison between cells incubated with and without antibody that is sufficiently accurate for the purposes of this paper.
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where T,, is the initial concentration of '251-~-BuTx, R0 is the initial concentration of receptor, expressed in a-BuTx-binding sites, and R and Tare were performed with an immunoglobulin fraction purified by passage over a DEAE column and, in some cases, by further fractionation on a Sephacryl S-200 column. Details of the preparations are given in Hall et al. (1985) and in Silberstein et al. (1983) . Similar results were obtained with both preparations of antibody. Myotubes grown on coverslips were incubated with 2 mg/ml of antibody in a total volume of 200 ~1 for 60 min followed by fluorescein-conjugated goat anti-human IgG F* fragment (Cappel Laboratories) and rhodamine-conjugated c~-BuTx. In some experiments, the rhodaVol. 5, No. 7, July 1985 were grown in 24.well plates and were incubated for 2 h at 37°C in 0.2 ml of the myasthenic antibodies at the indicated concentrations.
Binding of '251-ol-BuTx was then measured as described under "Materials and Methods." Determinations were made in duplicate. In this experiment, the 100% value was 14 fmol/well. Ab, antibody. AChR turnover. C2 myotubes grown in collagen-coated 24-well plates were incubated with 4 mg/ml of antibody or buffer for 2 hr at 37°C. The receptors were then labeled with '?a-BuTx.
The radioactivity released into the culture medium was monitored as described under "Materials and Methods." Determinations were made in duplicate. In this experiment, the 100% value in the absence of antibody (-Ab) was 89.1 + 4.0 fmol/well (n = 4). and the 100% value in the presence of antibody (+Ab) ws 51.6 + 4.5 fmol/well (n = 6). The half-lives (Lb) of the AChR in the presence and absence of antibody were 10.4 and 13 hr, respectively. solubilized AChRs from denervated rat muscle or from Torpedo electric organ (Hall et al., 1983 (Hall et al., , 1985 Minutes AChRs, and then followed the rate of receptor degradation by the previous results on C2 myotubes (Miller, 1984) . Preincubation with appearance of radioactivity in the medium. P-2 column chromatogthe myasthenic antibodies resulted in a decrease in the half-time of raphy was used to separate degradation products from intact toxin degradation to 10.4 hr (Fig. 3) . No further increase in the degradation released by dissociation. The results indicated (Fig. 3) that, although rate of myasthenic antibody-treated myotubes was seen on addition the antibodies had little or no effect on dissociation of toxin-receptor of a second antibody.
In some experiments toxin was added before complex, the rate of degradation of the complex was slightly inthe myasthenid antibodies. In these cases, the antibodies also creased.
Thus, the half-time of degradation of surface AChRs meascaused an increase in degradation that was similar to that seen ured in the absence of antibody was 13 hr, in agreement with when antibody was added before toxin (data not shown). AChR complex formation in the presence and absence of dTC. C2 ceils were rinsed and preincubated with different concentrations of dTC or buffer for 20 min at room temperature.
The solution was then replaced by the same solution containing IO nM 'Z51-ol-B~T~. '251-~-BuT~. AChR complex formation was monitored at different time points. This experiment demonstrated that the '%Y-BuTx.AChR complex formation was Irnear for at least 10 min under the conditions used. figure  7 . dTC inhibits the initial rate of (YBuTx binding to AChRs on C2 myotubes. C2 myotubes in 24.well plates were preincubated at room temperature for 20 mln with the indicated concentrations of dTC, followed by the same solution containing 10 nM '251-a-BuTx. The amount of bound toxin in 10 min was then determined as described under "Materials and Methods."
The data shown were taken from five independent experiments. All individual values were duplicates and each point represents the mean f SE. The solid l i ne is a theoretical curve expressing inhibition by two independent sites of equal concentration, of which the dissociation constants for dTC are 5.6 X lo-' and 1.6 X 1Om6 M, respectively. The antibodies bind to one of the two toxin-binding sites. Each AChR has two toxin-binding sites associated with each of the two a-subunits that the receptor possesses. One possible explanation for the partial inhibition of toxin binding by the myasthenic antibodies is that the antibodies bind to only one of the two toxin-binding sites on each AChR. This could occur either because the antibodies recognize specifically one of the two sites, or because nonselecGve binding of antibody to either of the two sites blocks binding to the other. Sine and Taylor (1979 , 1980 , 1981 have carried out an extensive study of the toxin-binding sites of the AChRs of BCSH-I , a non-fusing mouse muscle cell line. We have used an analysis similar to theirs to investigate the specificity of binding of the myasthenic antibodies to the AChR of C2 myotubes. When the binding of a-BuTx to C2 myotubes was measured, kinetic analysis showed a single association rate constant of 2.6 X IO4 M-'s-' (Fig. 4) . Thus, as in BC3H-1 cells, the two toxin-binding sites have identical, or closely similar, association rate constants for toxin binding.
We also examined the kinetics of toxin binding after incubation with antibody (Fig. 5) . The sites remaining after antibody Vol. 5, No. 7, July 1985 80 60 Log (dTC) Figure 8 . Effect of partial block of a-BuTx-brnding sites on I&/& ratio. C2 myotubes were incubated with 2.5 nM unlabeled WBUTX for 1.5 to 2 hr at 37°C. After extensive washing, the cells were incubated with dTC and then with '251-~-BuT~ as described in the legend to Figure 7 . The data were from two independent experiments in which the number of active sites was reduced by unlabeled WBUTX to 52% and 25%. The so/id curve is the same curve that is shown in Figure 7 . treatment showed an association rate constant of 1.5 X 10" M-'SC', a value that is about 40% lower than that seen in control myotubes. The decrease could result from reduced accessibility of the remaining binding sites to toxin or to a change in conformation of the AChR induced by antibody binding. The initial rate of binding of '"51-ol-B~T~ to the AChR was also decreased by dTC (Fig. 6 ). The inhibition occurred over a broad range of dTC concentrations, extending from lo-@ to 10m5 M (Fig.  7) . Analysis of the inhibition curve showed that the data were well fit by assuming that there are two independent sites, equal in number, with dissociation constants of 5.6 X 1 O-* M and 1.6 X I Om6 M. The data for dTC inhibition could also be explained by negatively cooperative interactions between two kinetically identical sites. According to such a model, the two sites would initially have indistinguishable affinities for dTC, but binding to one site would reduce the affinity of the other for dTC. This possibility was examined by blocking a fraction of the binding sites with unlabeled a-BuTx; dTC inhibition of '251-a-B~Tx binding to the remaining sites was then determined. In two experiments in which 75% and 48% of the sites were blocked, the inhibition curves that were obtained (Fig. 8) were similar to that seen in the absence of unlabeled toxin. These results are consistent with the interpretation that there are two independent sites.
We then examined the effect of antibody on the inhibition by dTC.
In the experiment shown in Figure 9 , the added antibody reduced the total number of toxin-binding sites by 40%. This decrease could have come about in three ways: (a) selective loss of high affinity dTC sites; (b) selective loss of the low affinity dTC sites; or (c) the loss of equal numbers of both sites. Theoretical curves for each of these possibilities were made, assuming that the antibody causes no change in either Kn or KS, the dissociation constants for the two sites (Fig. 9) . The data were best fit by the model in which the antibody caused selective loss of the high affinity site. We therefore conclude that the antibodies in the myasthenic serum selectively block toxin binding to one of the two toxin-binding sites on the AChR.
Discussion
The nicotinic AChR has two sites that bind agonists, antagonists, and elapid neurotoxins. Presumably these are structurally similar sites, since they are associated with the two a-subunits that the receptor contains (reviewed in Karlin, 1980; Conti-Tronconi and Raftery, 1982; Changeux et al., 1984) . Experiments with affinityalkylating agents (Damle and Karlin, 1978; Wolosin et al., 1980) and direct binding studies (Neubig and Cohen, 1979; Fels et al., 1982) with agonists and antagonists have established that, in Torpedo AChRs, the two sites are nonidentical. An extensive and elegant analysis of the two sites of the muscle AChR has been carried out Figure 9 . Incubation with myasthenic antibodies specifically blocked toxin binding to the site with high affinity for dTC. Experiments were carried out as described in the legend to Figure  7 , except that cells were preincubated with 4 mg/ ml of myasthenic antibody for 2 hr at 37°C. Each point represents the mean f SE of four determinations Incubation of cells with the antibody reduced total toxin binding, assayed under saturating conditions, to 60% of that seen without antibody.
The solid curves were calculated by using the values for the dissociation constants obtained in Figure 7 and by assuming that the 40% sites blocked by the antibody were either all low affinity sites (Na = 0.83, Ne = 0.17) all high affinity sites (Na = 0.17, Ns = 0.83) or equally shared between the two sites (Nn = 0.5, Ne = 0.5).
-9 -0 -7 -6 -5 -4 log Cd-tubocurarind by Sine and Taylor (1979 , 1980 , 1981 Noda et al., 1983; Klarsfeld et al., 1984) and that the two a-subunits have identical amino acid sequences over the portions of the chain that have been analyzed (Raftery et al., 1980; Conti-Tronconi et al., 1982 , 1984 , differential transcription or processing could give rise to small differences in the peptide backbone. Post-translational modifications that distinguish the two a-chains could also be the source of the different reactivity to the myasthenic antibodies, The cDNA sequence of the a-subunit indicates that there is a single site for glycosylation that is adjacent to the active site (Noda et al., 1982; Sumikawa et al., 1982; DevillersThiery et al., 1983) , and recent biochemical experiments indicate that the two a-subunits differ in the extent of their glycosylation (Conti-Tronconi et al., 1984 The effect of the antibodies described here on the physiological response to agonists of the AChRs in C2 myotubes is described in the following paper (Maricq et al., 1985) .
